A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Stage II-III Breast Cancer
Interventions: DRUG: cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)|DRUG: anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)|DRUG: traditional herbal medicine
Sponsor: Shengjing Hospital